MFWM
RARE icon

Motley Fool Wealth Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Motley Fool Wealth Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-222,981
Closed -$4.67M – 86
2026
Q1 		$4.67M Sell
222,981
-74,505
-25% -$1.68M 0.53% 66
2025
Q4 		$6.84M Sell
297,486
-58,054
-16% -$1.91M 0.53% 67
2025
Q3 		$10.7M Buy
355,540
+80,458
+29% +$2.41M 0.73% 50
2025
Q2 		$10M Buy
275,082
+125,486
+84% +$4.52M 0.6% 57
2025
Q1 		$5.42M Sell
149,596
-4,239
-3% -$176K 0.32% 97
2024
Q4 		$6.43M Sell
153,835
-14,180
-8% -$703K 0.33% 91
2024
Q3 		$9.33M Sell
168,015
-2,385
-1% -$121K 0.47% 75
2024
Q2 		$7.01M Buy
170,400
+6,324
+4% +$270K 0.36% 88
2024
Q1 		$7.66M Sell
164,076
-159
-0.1% -$7.5K 0.4% 78
2023
Q4 		$7.86M Sell
164,235
-4,024
-2% -$156K 0.41% 77
2023
Q3 		$6M Buy
168,259
+58,139
+53% +$2.3M 0.35% 86
2023
Q2 		$5.08M Buy
110,120
+4
+0% +$186 0.3% 89
2023
Q1 		$4.42M Buy
110,116
+55,232
+101% +$2.37M 0.28% 87
2022
Q4 		$2.54M Sell
54,884
-1,134
-2% -$44.6K 0.18% 98
2022
Q3 		$2.32M Buy
56,018
+58
+0.1% +$2.98K 0.15% 106
2022
Q2 		$3.34M Sell
55,960
-255
-0.5% -$15.7K 0.21% 96
2022
Q1 		$4.08M Buy
56,215
+71
+0.1% +$4.94K 0.2% 98
2021
Q4 		$4.72M Sell
56,144
-1,948
-3% -$159K 0.21% 93
2021
Q3 		$5.24M Sell
58,092
-1,179
-2% -$107K 0.23% 83
2021
Q2 		$5.65M Sell
59,271
-441
-0.7% -$45.9K 0.24% 89
2021
Q1 		$6.8M Buy
+59,712
New +$8.13M 0.31% 86

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Motley Fool Wealth Management's RARE Position: Q2 2026 in Review

Motley Fool Wealth Management sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2026, closing a stake of 222,981 shares — an estimated $4.67M sold.

Motley Fool Wealth Management first reported a position in RARE in Q1 2021 and held it in 21 quarters. The position peaked at $10.7M in Q3 2025. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Motley Fool Wealth Management reported no remaining Ultragenyx Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • Motley Fool Wealth Management sold 222,981 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $4.67M.
  • Motley Fool Wealth Management first reported a position in Ultragenyx Pharmaceutical in Q1 2021 and held it in 21 quarters.
  • Motley Fool Wealth Management's Ultragenyx Pharmaceutical position peaked at $10.7M in Q3 2025.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Motley Fool Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.